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Abstract 
Background
Matrix metalloproteinase-3 (MMP3) is implicated in the pathogenesis and progression of
atherosclerotic lesions. Previous studies suggested that MMP3 expression is influenced by a
polymorphism (known as the 5A/6A polymorphism) in the promoter of the MMP3 gene and that
this polymorphism is located within a cis-element that interacts with the transcription factor NFκB.
In the present study, we sought to investigate whether MMP3 and NFκB were co-localized in
atherosclerotic lesions and whether NFκB had differential effects on the two alleles of the MMP3
5A/6A polymorphism.
Methodology/Principal Findings
Immunohistochemical examination showed that MMP3 and both the NFκB p50 and p65 subunits
were expressed abundantly in macrophages in atherosclerotic lesions and that MMP3 expression
was co-localized with p50 and p65. Chromatin immunoprecipitation experiments showed
interaction of p50 and p65 with the MMP3 promoter in macrophages, with greater binding to the
5A allele than to the 6A allele. Reporter gene assays in transiently transfected macrophages
showed that the 5A allele had greater transcriptional activity than the 6A allele, and that this
allele-specific effect was augmented when the cells were treated with the NFκB activator
lipopolysaccharides or co-transfected with p50 and/or p65 expressing plasmids, but was reduced
when the cells were treated with the NFκB inhibitor 6-Amino-4-(4-phenoxyphenylethylamino)-qu
inazoline or transfected with a dominant negative mutant of IkB kinase-β.
Conclusion
These results corroborate an effect of the 5A/6A polymorphism on MMP3 transcription and indicate
that NFκB has differential effects on the 5A and 6A alleles.
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INTRODUCTION 
Atherosclerotic plaque rupture is the most common cause of acute clinical ischemic events associated
with coronary artery disease [1]. A typical atherosclerotic plaque contains a lipid core covered by a
fibrous cap, and plaque rupture is mostly the result of fibrous cap fissuring [1], [2]. There is evidence
indicating that increased expression of matrix metalloproteinase-3 (MMP3) in the atherosclerotic
plaque promotes plaque rupture [3]–[5]. MMP3 is abundantly expressed by macrophages in
atherosclerotic plaques, particularly in the lateral regions of the fibrous cap where fissuring is most
likely to occur [3], [4]. This protease is capable of degrading several major structural matrix proteins
present in atherosclerotic plaques [6], [7]. A study of a mouse model of atherosclerosis has shown
that knocking out MMP3 results in increased amounts of matrix proteins in atherosclerotic lesions, a
feature of more stable plaques [5].
The transcription of the MMP3 gene is tightly regulated [8]. We and others have shown that its
transcription is influenced by a polymorphism in the promoter of the gene [9], [10]. The polymorphism
(dbSNP ID rs3025058), known as the 5A/6A polymorphism, is due to a single base deletion (or
insertion) in a run of thymidines, resulting in one allele (the 5A allele) having 5 thymidines and the
other allele (the 6A allele) having 6 thymidines, at nucleotide positions from −1608 to −1612 (or
−1613) relative to the transcription start site. Previously studies by our and other groups have
demonstrated that the 5A allele has greater promoter activity than the 6A allele [9], [10]. In
agreement, it has also been shown that MMP3 mRNA and protein levels in arterial tissues are higher in
individuals who are homozygous for the 5A allele than in those who are homozygous for the 6A allele,
with intermediate levels in heterozygous individuals [11]. Genetic epidemiological studies have shown
an association between the 5A allele and increased risk of myocardial infarction and several other
cardiovascular disorders [12]–[15].
MMP3 transcription is modulated by the transcription factor NFκB [16]–[19] and there is evidence
indicating that the DNA sequence encompassing the 5A/6A polymorphic site can interact with NFκB
[20]. In the present study, we sought to investigate whether MMP3 and NFκB were co-expressed in
atherosclerotic lesions and to characterize the regulatory effect of NFκB on the MMP3 gene 5A and 6A
alleles.
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RESULTS 
We carried out an immunohistochemical analysis to determine whether MMP3 and NFκB were
co-expressed in atherosclerotic lesions. The analysis showed that MMP3 and both the NFκB p50 and
p65 subunits were expressed abundantly in macrophages in atherosclerotic lesions and were also
present in smooth muscle cells in these tissues (Figure 1). Importantly, we found that MMP3
expression was co-localized with p50 and p65 in these lesions, although this was not seen in every cell
(Figure 2).
Figure 1. Macrophages and smooth muscle cells in atherosclerotic plaques
express MMP3 and NFκB.
Sections (4 µm) of paraffin embedded tissue blocks of atherosclerotic plaques were subjected to
double immunostaining of MMP3 and the macrophage marker CD68 (A and B), MMP3 and the
smooth muscle cell marker SMA (C and D), p50 and CD68 (E and F), p50 and SMA (G and H), p65
and CD68 (I and J), p65 and SMA (K and M), using rabbit polyclonal NFκB p50 and MMP3 antibodies
(Abcam), a rabbit monoclonal NFκB p65 antibody (Abcam), and mouse monoclonal CD68 and
smooth muscle actin (SMA) antibodies (DAKO), respectively, and goat anti-rabbit or anti-mouse
secondary antibodies (Thermo/LabVision). The double immunostaining was visualized with Liquid
Permanent Red chromogen (Dako) and Vector Blue chromogen (Vector Labs). Pink colour indicates
expression of MMP3 (A, B, C and D), p50 (E, F, G and H) or p65 (I, J, K and M). Blue colour
indicates expression of CD68 (A, B, E, F, I and J) or SMA (C, D, G, H, K and M). Arrow indicates cell
co-expressing MMP3 with CD68 (B) or SMA (D), p50 with CD68 (F) or SMA (H), and p65 with CD68
(J) or SMA (M). 200X magnification in A, C, E, G, I and K; 400X magnification in B, D, F, H, J and
M.
doi:10.1371/journal.pone.0009902.g001
Figure 2. MMP3 and NFκB are co-localized in atherosclerotic plaques.
Sections (4 µm) of paraffin embedded tissue blocks of atherosclerotic plaques were
subjected to double immunostaining of MMP3 and p50 (A, B, and C) or MMP3 and p65 (D, E and F),
using rabbit polyclonal NFκB p50 and MMP3 antibodies (Abcam) and a rabbit monoclonal NFκB p65
antibody (Abcam), respectively, and goat anti-rabbit secondary antibodies (Thermo/LabVision). The
double immunostaining was visualized with Liquid Permanent Red chromogen (Dako) and Vector
Blue chromogen (Vector Labs). Pink colour indicates expression of p50 (A, B and C) or p65 (D, E
and F). Blue colour indicates expression of MMP3 (A, B, C, D, E and F. Arrow indicates cell
co-expressing MMP3 with p50 (B and C) or with p65 (E and F). 200× magnification in A and D;
400× magnification in B, C, E and F.
doi:10.1371/journal.pone.0009902.g002
We then performed chromatin immunoprecipitation experiments in THP1 monocytes to study whether
NFκB could interact with the MMP3 gene promoter. The experiments showed binding of p50 and p65 to
the MMP3 promoter in these cells (Figure 3).
Figure 3. Interaction of p50 and p65 with MMP3 gene promoter.
Chromatin proteins and DNA in THP1 cells were cross-linked in 1% formaldehyde for
10 minutes. Cells were then lysed, and the lysate sonicated to reduce DNA length to
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200–1000 bp. The sonicated chromatin was subjected to immunoprecipitation using a p50 or p65
antibody, with rabbit IgG as a control, followed by PCR amplification of 406 bp and 407 bp DNA
fragments surrounding the MMP3 gene 5A/6A site and then agarose gel electrophoresis of the PCR
products. Intensity of bands on the agarose gels were quantified with the computer software
ImageJ. The fold enrichment of DNA precipitated with p50 antibody or p65 antibody, relative to the
IgG control, was calculated by comparing the intensity of the band of the amplicon from the p50 or
p65 antibody precipitate to the intensity of the band of the amplicon from the IgG control. The
graph shows fold enrichments of DNA precipitated with p50 antibody or p65 antibody, relative to
the IgG control. Data shown are mean (± standard error of mean) from four independent
experiments. * denotes p<0.05 comparing DNA precipitated with p50 antibody or p65 antibody to
the IgG control.
doi:10.1371/journal.pone.0009902.g003
We then investigated whether the MMP3 5A/6A polymorphism had an effect on NFκB binding. Using
the THP1 cell line (these cells are heterozygous for the MMP3 5A/6A polymorphism), we compared the
relative amounts of chromatins of the 5A and 6A alleles respectively, precipitated using anti-NFκB
antibodies. We found that both an anti-p50 antibody and an anti-p65 antibody precipitated greater
amount of 5A allele chromatin than 6A allele chromatin (Figure 4), suggesting that NFκB interacted
more readily with the 5A allele than the 6A allele.
Figure 4. The MMP3 gene 5A allele more readily interacts with p50 and p65,
than the 6A allele.
Chromatin proteins and DNA in THP1 cells were cross-linked in1% formaldehyde for 10
minutes. Cells were then lysed, and the lysate sonicated to reduce DNA length to 200–1000 bp. The
sonicated chromatin was subjected to immunoprecipitation using a p50 or p65 antibody, or
incubated with a rabbit IgG, followed by PCR amplification of 179 bp and 180 bp DNA fragments
surrounding the MMP3 gene 5A/6A site using fluorescence labelled primers. The PCR amplicons
were analyzed using an ABI 3730xl analyzer and Genemapper software. Three independent
experiments were performed. (A). Representative output from the Genemapper programme. The
panels from top to bottom represent input chromatin DNA, chromatin immunoprecipitated with the
p50 antibody, and chromatin immunoprecipitated with the p65 antibody. (B). Chart shows mean (±
standard error of mean) of the relative peak heights of the 5A and 6A alleles in the p50 and p65
antibody precipitates, standardized against the relative peak heights of the 5A and 6A alleles in the
input DNA, in three independent experiments. * denotes p<0.05 comparing 5A versus 6A alleles.
doi:10.1371/journal.pone.0009902.g004
To further characterize the effect of NFκB on MMP3 5A and 6A alleles, we performed transfection and
luciferase reporter assays in which macrophages were transfected with plasmids containing a MMP3
gene promoter sequence corresponding to either the 5A or 6A allele and a firefly luciferase reporter
gene, and treated the transfected cells with lipopolysaccharide (LPS), an endotoxin stimulus of NFκB
activation. These experiments demonstrated that without LPS stimulation, luciferase activity in cells
transfected with the 5A allele construct was 2.4 fold greater than that in cells transfected with the 6A
allele construct (p<0.01), confirming that the 5A allele has higher promoter activity than the 6A allele
(Figure 5). More importantly, the experiments showed that in cells transfected with the 5A allele
construct, luciferase activity was increased by LPS treatment, whereas in cells transfected with the 6A
allele construct, LPS treatment did not increase luciferase activity (Figure 5), which is consistent with
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the notion that NFκB acts more effectively on the 5A allele than the 6A allele.
Figure 5. Lipopolysaccharide increases 5A allele activity.
RAW264 cells were transfected with an MMP3 5A-firefly luciferase reporter plasmid or
an MMP3 6A-firefly luciferase reporter plasmid, and the pRL-TK plasmid (expressing
renilla luciferase) to serve as a reference for transfection efficiency. Transfected cells were cultured
for 24 hours in the absence or presence of lipopolysaccharides. Luciferase reporter assay was
performed using a dual-luciferase reporter assay system. Data shown are mean (± standard error
of mean) of the ratio of firefly luciferase activity over renilla luciferase activity from four
independent experiments. Asterisk indicates p<0.05 comparing untreated 5A and LPS treated 5A.
doi:10.1371/journal.pone.0009902.g005
To verify that NFκB has differential effects on the 5A and 6A alleles, we co-transfected macrophages
(RAW264 cells) with the 5A or 6A construct together with p50 and/or p65 expressing plasmids. The
experiment showed that over-expressing p50 or p65 resulted in an increase in luciferase activity in
cells transfected with the 5A construct and this upregulatory effect was further increased when both
the p50 and p65 subunits were overexpressed (Figure 6). In contrast, in cells transfected with the 6A
construct, there was only a small increase in luciferase activity only when both the p50 and p65
subunits were overexpressed (Figure 6).
Figure 6. NFκB has a greater upregulatory effect on the 5A allele than the 6A
allele.
RAW264 cells were transfected with an MMP3 5A-firefly luciferase reporter plasmid or
an MMP3 6A-firefly luciferase reporter plasmid, and the pRL-TK plasmid (expressing renilla
luciferase) to serve as a reference for transfection efficiency, together with a plasmid expressing
p50 and/or a plasmid expressing p65. Luciferase reporter assay was performed using a
dual-luciferase reporter assay system. Data shown are mean (± standard error of mean) of the
ratio of firefly luciferase activity over renilla luciferase activity from four independent experiments.
In panel (A), * indicates p = 0.07 comparing 5A and 5A plus p50. In panel (B), ** indicates p<0.01
comparing 5A and 5A plus p65. In panel (C), * denotes p<0.05 comparing 5A with 5A plus p50 and
p65.
doi:10.1371/journal.pone.0009902.g006
To further verify the effect of NFκB, we examined whether the NFκB inhibitor 6-Amino-
4-(4-phenoxyphenylethylamino)-quinazoline had an effect on luciferase activity in cells transfected
with the 5A or 6A construct. The experiment showed that the NFκB inhibitor reduced luciferase
activity, most notably in cells transfected with the 5A allele construct (Figure 7).
Figure 7. NFκB inhibitor has a suppressive effect.
RAW264 cells were transfected with an MMP3 5A-firefly luciferase reporter plasmid or
an MMP3 6A-firefly luciferase reporter plasmid, and the pRL-TK plasmid (expressing
renilla luciferase) to serve as a reference for transfection efficiency. Transfected cells were cultured
for 24 hours in the absence or presence of the NFκB inhibitor 6-Amino-
4-(4-phenoxyphenylethylamino)-quinazoline (10 µM concentration). Luciferase reporter assay was
performed using a dual-luciferase reporter assay system. Data shown are mean (± standard error
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of mean) of the ratio of firefly luciferase activity over renilla luciferase activity from three
independent experiments. * indicates p<0.05 comparing 5A with 5A plus NFκB inhibitor.
doi:10.1371/journal.pone.0009902.g007
Since NFκB is activated through the action of IkB kinases (IKK), we investigated whether suppression
of IKK activity would have differential effects on the 5A and 6A alleles. The experiment showed that
expression of a dominant negative mutant of IKKβ resulted in a significant reduction in luciferase
activity, especially in cells transfected with the 5A allele construct which showed a 60% reduction
(p<0.01, Figure 8).
Figure 8. Expressing a dominant negative mutant of IKKβ has a suppressive
effect.
RAW264 cells were transfected with an MMP3 5A-firefly luciferase reporter plasmid or
an MMP3 6A-firefly luciferase reporter plasmid, and the pRL-TK plasmid (expressing renilla
luciferase) to serve as a reference for transfection efficiency, together with a plasmid expressing a
dominant negative mutant of IKKβ. Luciferase reporter assay was performed using a dual-luciferase
reporter assay system. Data shown are mean (± standard error of mean) of the ratio of firefly
luciferase activity over renilla luciferase activity from three independent experiments. ** indicates
p<0.01 comparing 5A with 5A plus IKKbeta dominate negative mutant; and * indicates p<0.05
comparing 6A with 6A plus IKKbeta dominate negative mutant.
doi:10.1371/journal.pone.0009902.g008
DISCUSSION 
Our study demonstrates that MMP3 and NFκB are colocalized in macrophages and smooth muscle cells
in atherosclerotic plaques. With the use of the chromatin immunoprecipitation technique, we showed
that NFκB can interact with the MMP3 gene promoter and that this transcription factor binds more
readily to the 5A allele than the 6A allele. In line with this finding, reporter assays in transiently
transfected macrophages showed that the 5A allele has greater transcriptional activity than the 6A
allele, and that this allele-specific effect was augmented in cells treated with the NFκB activator LPS or
co-transfected with p50 and/or p65 expressing plasmids, but was reduced when the cells were treated
with the NFκB inhibitor 6-Amino-4-(4-phenoxyphenylethylamino)-quinazoline or transfected with a
dominant negative mutant of IkB kinase-β. Taken together, these results indicate that the 5A/6A
polymorphism influences MMP3 transcription due to differential effects of NFκB on the 5A and 6A
alleles.
MMP3 has proteolytic activity on types III, IV and V collagen, proteoglycans, laminin, fibronectin and
elastin [6], [7], which are the principal components of the extracellular matrix of the arterial wall and
provide the strength of the atherosclerotic plaque to withstand the mechanical stress imposed on it by
the blood circulation [21]. In addition, MMP3 is an activator of several other MMPs including MMP-1,
-7, -8, -9 and -13 [22]–[24] which are also important players in atherogenesis and plaque rupture
[4], [25]–[28]. There is evidence indicating that increased MMP3 expression in atherosclerotic plaque
renders the plaque prone to rupture [3]–[5]. Plaque rupture is the most common cause of acute
clinical ischemic events such as myocardial infarction and stroke [1]. Thus, an insight into the
molecular mechanisms that govern the regulation of MMP3 expression will enhance our understanding
of the pathogenesis of atherosclerosis and plaque rupture.
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It is now widely accepted that atherosclerosis is a chronic inflammatory disease of the vessel wall [29].
NFκB is a key regulator of inflammation and can mediate the induction of more than 160 genes, many
of which have a documented role in atherosclerosis [30]. Previous studies have shown that NFκB plays
an important role in the regulation of MMP3 expression [16]–[19]. However, the element(s) in the
MMP3 gene that mediate(s) the regulatory effect of NFκB had not yet been identified. Our present
study indicates that the sequence encompassing the 5A/6A site is likely to be an NFκB responsive site.
The 5A/6A polymorphism has been associated with risk of myocardial infarction [12], [13], [31]. In
addition, it has been associated with several other cardiovascular diseases including cardiac mortality
in patients with heart failure [32], coronary aneurysm [33], restenosis after coronary angioplasty
[34], [35], carotid atherosclerosis and stroke [36]–[38]. Studies have shown that MMP3 mRNA and
protein levels in ex vivo tissues including arteries are highest in 5A homozygotes, intermediate in
heterozygotes and lowest in 6A homozygotes [11], [39], and that the 5A allele has greater promoter
activity and MMP3 transcription than the 6A allele [9], [10], although the molecular mechanism
underlying the effect of this polymorphism on MMP3 gene promoter activity and transcription is
unclear. The results of the present study corroborate the regulatory effect of the 5A/6A polymorphism
and indicate that this effect is likely to derive from differential effects of NFκB on the 5A and 6A
alleles.
In conclusion, the findings of this study are highly relevant to the understanding of the transcriptional
regulation of MMP3, increased expression of which has been suggested to play an important role in
atherosclerotic plaque rupture [3]–[5]. In addition, they provide an insight into the functional effect of
the 5A/6A polymorphism which has been associated with a number of cardiovascular traits including
risk of myocardial infarction [14].
MATERIALS AND METHODS 
Chemicals
Lipopolysaccharide was obtained from Sigma. 6-Amino-4-(4-phenoxyphenylethylamino)- quinazoline
was from Merck Chemicals Ltd. Antibodies for p50 (ab7971), p65 (ab32536 and ab7970) and MMP3
(ab53015) were from Abcam. ChIP assay kit was from Upstate Biotechnology.
Immunohistochemistry
Immunohistochemical analyses were performed on 4 µm sections of formalin-fixed and paraffin-
embedded tissue blocks of atherosclerotic plaques removed from patients undergoing carotid
endarterectomy. The study was approved by the South and West Local Research Ethics Committee,
and all participants provided written informed consent. Tissue sections were pretreated with Tris-EDTA
pH 9.0. Immunostaining was carried out as described previously [40]. We used rabbit polyclonal NFκB
p50 (ab7971, Abcam) and MMP3 antibodies (ab53015, Abcam), a rabbit monoclonal NFκB p65
antibody (ab32536, Abcam), and mouse monoclonal CD68 (clone PG-M1) and smooth muscle
alpha-actin (SMA, clone 1A4) antibodies (Dako, Glostrup, Denmark), respectively. Secondary
antibodies were goat anti-mouse IgG or anti-rabbit IgG/alkaline phosphatase (AP) polymers
(Thermo/LabVision, Fremont, CA). The sequential AP double immunostaining was performed as
previously described [41] with Liquid Permanent Red (Dako) and Vector Blue used as chromogens
(Vector Labs, Burlingame, CA).
Cell culture
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THP1 and RAW264 cells were purchased from the American Type Culture Collection (ATCC) and the
European Collection of Cell Cultures (ECACC), respectively. THP1 cells were maintained in RPMI-1640
medium (ATCC) supplemented with 10% foetal bovine serum (Invitrogen), 2 mM L-glutamine
(Invitrogen), 50 U/ml penicillin and 50 µg/ml streptomycin (Invitrogen). RAW264 cells were
maintained in DMEM medium (Sigma) supplemented with 10% foetal bovine serum (Invitrogen), 2 mM
L-glutamine (Invitrogen), 50 U/ml penicillin and 50 µg/ml streptomycin (Invitrogen). The cells were
incubated at 37°C in a cell incubator supplied with 5% CO2.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out by using a chromatin immunoprecipitation kit from
Upstate Biotechnology according to the manufacturer manual. Briefly, THP1 cells were grown to
density at 0.8–1×106 cells per ml of culture medium. Proteins were cross-linked to DNA by adding
37% of formaldehyde directly to the medium to a final concentration of 1%, and after 10 minutes of
incubation at room temperature, unreacted formaldehyde was quenched with 0.125 M glycine for 5
minutes. Cells were pelleted, washed 2–3 times in ice-cold phosphate buffered saline and lysed in lysis
buffer with protease inhibitors for 10 minutes on ice. The lysate was sonicated to reduce DNA length to
200–1000 bp and then spun at 10,000 g at 4°C for 10 minutes to remove insoluble materials.
Immunoprecipitation of chromatin was performed by incubation with 2 µg anti-p50 antibody (ab7971,
Abcam) or 2 µg anti-p65 antibody (ab7970, Abcam) at 4°C for 18 hours. Incubation with 2 µg rabbit
IgG was used as a control. Following the immunoprecipitation, PCR was carried out to amplify the DNA
sequence surrounding the MMP3 gene 5A/6A site, followed by agarose gel electrophoresis of the PCR
products. Intensity of bands on the agarose gels were quantified with the computer software ImageJ.
The fold enrichment of DNA precipitated with p50 antibody or p65 antibody, relative to the IgG
control, was calculated by comparing the intensity of the band of the amplicon from the p50 or p65
antibody precipitate to the intensity of the band of the amplicon from the IgG control. Four
independent experiments were carried out.
Analysis of chromatin immunoprecipitation products
To detect chromatin immunoprecipitates, purified DNA was analyzed by PCR using specific MMP3
promoter primers covering the 5A/6A polymorphic site: 5′-AATTCACATCACTGCCACCA-3′ and
5′-CTCTGTGGCAATAAGATCCC-3′, and PCR products were analysed on 2% agarose gels with GelRed
staining. Intensity of bands on the agarose gels were quantified with the computer software ImageJ.
To compare the relative amounts of the 5A and 6A alleles in the chromatin immunoprecipitates,
purified DNA obtained from chromatin immunoprecipitation was subject to PCR with a 6-FAM-labelled
forward primer (5′-AATTCACATCACTGCCACCA-3′) and an unlabelled reverse primer
(5′-GATTACAGACATGGGTCACG-3′) flanking the 5A/6A polymorphic site, with expected amplicons of
179 bp from the 5A allele and 180 bp from the 6A allele. The PCR reactions were carried out using
Phire Hot Start DNA polymerase to generate blunt ended PCR products. The fluorescence labelled PCR
fragments were analyzed using an ABI 3730xl analyzer and Genemapper software. Three independent
experiments were performed. The relative peak heights of the 5A and 6A alleles in the p50 and p65
antibody precipitates were standardized against the relative peak heights of the 5A and 6A alleles in
the input DNA and compared by a t-test.
Plasmids
The MMP3 5A and 6A pGL3 reporter constructs were produced by cloning three copies of the 5A or 6A
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polymorphic site of the human MMP3 gene: 5′-ACAAGACATGGTTTTT(T)CCCCCCATCAAAGA-3′ into the
pGL3 promoter vector (Promega), upstream of the SV40 promoter and the luciferase gene. NFκB p50,
NFκB p65 and p300 expressing plasmids have been described [42]–[44]. The IKKβ dominate negative
plasmid has been described previously [45].
Transfection and luciferase reporter assay
The day before transfection, RAW264 cells were plated into 24-well tissue culture dishes at a density
reaching 70–80% confluence by the following day. Cells were transfected with the MMP3 5A-luciferase
reporter plasmid or the MMP3 6A-luciferase reporter plasmid, and the pRL-TK plasmid (Promega) to
serve as a reference for transfection efficiency. Transfected cells were cultured for 24 hours in the
absence or presence of LPS (100 ng/ml) or 6-Amino-4-(4-phenoxyphenylethylamino)-quinazoline (10
µM). In some experiments, the cells were also transfected with a p50 expression plasmid and/or a p65
expression plasmid, or with a pcDNA3 plasmid to serve as a control, or with a plasmid expressing a
dominant negative mutant of IKKβ. Transfections were performed in duplicates with FuGENE 6
transfection reagent (Roche) using a protocol provided by the supplier. Luciferase reporter assay was
performed using a dual-luciferase reporter assay system (Promega). Transfections and cell treatments
were performed in duplicate and individual experiments were repeated at least three times.
Statistical analysis
In the chromatin immunoprecipitation assays, the PCR band itensities of DNA precipitated with p50
antibody or p65 antibody were compared with the IgG control by Mann-Whitney test. The relative
peak heights of the 5A and 6A alleles in the p50 and p65 antibody precipitates in the Genemaper
programme outputs were standardized against the relative peak heights of the 5A and 6A alleles in
the input DNA and compared by a t-test. In the luciferases reporter assays, t-tests were performed to
compare differences between the 5A and 6A alleles and between different the treated and untreated.
All data are represented as the mean ± standard error of mean (SEM).
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